Stuart Roger Lipsitz, Sc.D.
Co-Author
This page shows the publications co-authored by Stuart Lipsitz and Adam Kibel.
Connection Strength
2.667
-
Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis. 2020 03; 23(1):81-87.
Score: 0.205
-
Effect of Medicaid Expansion on Receipt of Definitive Treatment and Time to Treatment Initiation by Racial and Ethnic Minorities and at Minority-Serving Hospitals: A Patient-Level and Facility-Level Analysis of Breast, Colon, Lung, and Prostate Cancer. JCO Oncol Pract. 2021 05; 17(5):e654-e665.
Score: 0.058
-
Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer? J Comp Eff Res. 2021 06; 10(9):733-741.
Score: 0.058
-
Impact of high-intensity local treatment on overall survival in stage IV upper tract urothelial carcinoma. Urol Oncol. 2021 07; 39(7):436.e1-436.e10.
Score: 0.058
-
Reply by Authors. J Urol. 2021 05; 205(5):1274.
Score: 0.058
-
Systematic Review of Time to Definitive Treatment for Intermediate Risk and High Risk Prostate Cancer: Are Delays Associated with Worse Outcomes? J Urol. 2021 May; 205(5):1263-1274.
Score: 0.057
-
Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Netw Open. 2020 03 02; 3(3):e201839.
Score: 0.054
-
Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urol Oncol. 2020 03; 38(3):74.e13-74.e20.
Score: 0.053
-
Facility-Level Variation in Pelvic Lymphadenectomy During Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer. Ann Surg Oncol. 2020 Jun; 27(6):1929-1936.
Score: 0.053
-
Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2020 09; 23(3):410-418.
Score: 0.053
-
Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. J Immunother Cancer. 2019 11 07; 7(1):289.
Score: 0.053
-
Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. J Natl Compr Canc Netw. 2019 09 01; 17(9):1049-1058.
Score: 0.052
-
Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. Clin Genitourin Cancer. 2019 10; 17(5):e1060-e1068.
Score: 0.051
-
Sex-specific Differences in the Quality of Treatment of Muscle-invasive Bladder Cancer Do Not Explain the Overall Survival Discrepancy. Eur Urol Focus. 2021 01; 7(1):124-131.
Score: 0.051
-
Comparison of Hospital Readmission After Total Hip and Total Knee Arthroplasty vs Spinal Surgery After Implementation of the Hospital Readmissions Reduction Program. JAMA Netw Open. 2019 05 03; 2(5):e194634.
Score: 0.051
-
The current landscape of low-value care in men diagnosed with prostate cancer: what is the role of individual hospitals? Urol Oncol. 2019 09; 37(9):575.e9-575.e18.
Score: 0.051
-
Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. J Oncol Pract. 2019 06; 15(6):e547-e559.
Score: 0.051
-
Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. J Urol. 2019 04; 201(4):735-741.
Score: 0.051
-
Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. J Urol. 2019 04; 201(4):728-734.
Score: 0.051
-
Association of Care at Minority-Serving vs Non-Minority-Serving Hospitals With Use of Palliative Care Among Racial/Ethnic Minorities With Metastatic Cancer in the United States. JAMA Netw Open. 2019 02 01; 2(2):e187633.
Score: 0.050
-
Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz003.
Score: 0.050
-
Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clin Genitourin Cancer. 2019 06; 17(3):e488-e493.
Score: 0.050
-
Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival? Cancer. 2019 04 15; 125(8):1319-1329.
Score: 0.050
-
Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer. 2019 05 01; 125(9):1449-1458.
Score: 0.050
-
Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Ann Surg Oncol. 2019 Jan; 26(1):297-305.
Score: 0.049
-
Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. Eur Urol. 2019 04; 75(4):552-555.
Score: 0.049
-
Use of Preventive Health Services Among Cancer Survivors in the U.S. Am J Prev Med. 2018 12; 55(6):830-838.
Score: 0.049
-
Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference? Eur Urol Oncol. 2019 07; 2(4):349-354.
Score: 0.049
-
Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer Prostatic Dis. 2019 03; 22(1):125-136.
Score: 0.049
-
Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Can Urol Assoc J. 2019 Feb; 13(2):32-37.
Score: 0.048
-
Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2018 09; 200(3):573-581.
Score: 0.047
-
The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urol Oncol. 2018 05; 36(5):238.e7-238.e17.
Score: 0.047
-
Reassessing the value of high-volume cancer care in the era of precision medicine. Cancer. 2018 04 01; 124(7):1319-1321.
Score: 0.047
-
Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol. 2018 Feb 01; 4(2):225-229.
Score: 0.047
-
Comparative effectiveness of robot-assisted vs. open radical cystectomy. Urol Oncol. 2018 03; 36(3):88.e1-88.e9.
Score: 0.046
-
Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. Urol Oncol. 2018 02; 36(2):78.e13-78.e19.
Score: 0.046
-
Associations of specific postoperative complications with costs after radical cystectomy. BJU Int. 2018 03; 121(3):428-436.
Score: 0.046
-
Variation in the use of active surveillance for low-risk prostate cancer. Cancer. 2018 Jan 01; 124(1):55-64.
Score: 0.045
-
Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. Clin Genitourin Cancer. 2017 Aug 24.
Score: 0.045
-
Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. Eur Urol. 2018 Mar; 73(3):445-451.
Score: 0.045
-
The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database. J Urol. 2017 12; 198(6):1295-1300.
Score: 0.045
-
Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. J Urol. 2017 11; 198(5):1061-1068.
Score: 0.044
-
Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. Eur Urol. 2017 10; 72(4):483-487.
Score: 0.044
-
Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol. 2017 Mar 10; 35(8):852-860.
Score: 0.043
-
The association of hypoalbuminemia with early perioperative outcomes - A comprehensive assessment across 16 major procedures. Am J Surg. 2017 Nov; 214(5):871-883.
Score: 0.043
-
Prog Urol. 2016 Nov; 26(13):676-677.
Score: 0.043
-
Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. J Clin Oncol. 2016 10 10; 34(29):3529-3536.
Score: 0.043
-
Determinants of cancer screening in Asian-Americans. Cancer Causes Control. 2016 08; 27(8):989-98.
Score: 0.042
-
Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. J Urol. 2016 Oct; 196(4):1090-5.
Score: 0.041
-
Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol. 2016 Jan; 2(1):85-93.
Score: 0.040
-
Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States. Eur Urol. 2014 Sep; 66(3):569-76.
Score: 0.035
-
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol. 2012 Jun; 61(6):1239-44.
Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.